Cargando…
COVID-19 in a multiple sclerosis (MS) patient treated with alemtuzumab: Insight to the immune response after COVID
BACKGROUND: The severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2) is a novel disease that has spread abruptly over the world, allowing the development of countermeasures an urgent global priority. It has been speculated that elder people and patient with comorbidities may be at risk...
Autores principales: | Fiorella, Celsi, Lorna, Galleguillos |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier B.V.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7416707/ https://www.ncbi.nlm.nih.gov/pubmed/32835901 http://dx.doi.org/10.1016/j.msard.2020.102447 |
Ejemplares similares
-
COVID-19 and multiple sclerosis: A description of two cases on alemtuzumab
por: Fernández-Díaz, Eva, et al.
Publicado: (2020) -
Alemtuzumab in Covid era
por: Iovino, Aniello, et al.
Publicado: (2021) -
Mild COVID-19 infection in a patient with multiple sclerosis and severe depletion of T-lymphocyte subsets due to alemtuzumab
por: Guevara, Carlos, et al.
Publicado: (2020) -
Alemtuzumab for Multiple Sclerosis
por: Willis, Mark D., et al.
Publicado: (2016) -
The Meaning of Immune Reconstitution after Alemtuzumab Therapy in Multiple Sclerosis
por: Rolla, Simona, et al.
Publicado: (2020)